COVID-19 Impact on Global Antibacterial (Drug) Resistance, Market Insights and Forecast to 2026

1 Study Coverage

• 1.1 Antibacterial (Drug) Resistance Product Introduction
• 1.2 Market Segments
• 1.3 Key Antibacterial (Drug) Resistance Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type
  • 1.4.2 Telavancin (Vibativ)
  • 1.4.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
  • 1.4.4 Fidaxomicin (Dificid / Dificlir)
  • 1.4.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • 1.4.6 Dalbavancin (Dalvance/ Xydalba)
  • 1.4.7 Tedizolid Phosphate (Sivextro)
  • 1.4.8 Oritavancin (Orbactiv/ Nuvocid)
  • 1.4.9 Ceftolozane-Tazobactam (Zerbaxa)
  • 1.4.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • 1.4.11 PHASE III DRUGS
• 1.5 Market by Indication
  • 1.5.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Indication
  • 1.5.2 Complicated Urinary Tract Infection (CUTI)
  • 1.5.3 Complicated Intra-Abdominal Infections (CIAI)
  • 1.5.4 Blood Stream Infections (BSI)
  • 1.5.5 Clostridium Difficile Infections (CDI)
  • 1.5.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • 1.5.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • 1.5.8 Community Acquired Bacterial Pneumonia (CABP)
• 1.6 Coronavirus Disease 2019 (Covid-19): Antibacterial (Drug) Resistance Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Antibacterial (Drug) Resistance Industry
    • 1.6.1.1 Antibacterial (Drug) Resistance Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Antibacterial (Drug) Resistance Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Antibacterial (Drug) Resistance Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Executive Summary

• 2.1 Global Antibacterial (Drug) Resistance Market Size Estimates and Forecasts
  • 2.1.1 Global Antibacterial (Drug) Resistance Revenue 2015-2026
  • 2.1.2 Global Antibacterial (Drug) Resistance Sales 2015-2026
• 2.2 Antibacterial (Drug) Resistance Market Size by Region: 2020 Versus 2026
  • 2.2.1 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Antibacterial (Drug) Resistance Competitor Landscape by Players

• 3.1 Antibacterial (Drug) Resistance Sales by Manufacturers
  • 3.1.1 Antibacterial (Drug) Resistance Sales by Manufacturers (2015-2020)
  • 3.1.2 Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2015-2020)
• 3.2 Antibacterial (Drug) Resistance Revenue by Manufacturers
  • 3.2.1 Antibacterial (Drug) Resistance Revenue by Manufacturers (2015-2020)
  • 3.2.2 Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Antibacterial (Drug) Resistance Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Antibacterial (Drug) Resistance Revenue in 2019
  • 3.2.5 Global Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Antibacterial (Drug) Resistance Price by Manufacturers
• 3.4 Antibacterial (Drug) Resistance Manufacturing Base Distribution, Product Types
  • 3.4.1 Antibacterial (Drug) Resistance Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Antibacterial (Drug) Resistance Product Type
  • 3.4.3 Date of International Manufacturers Enter into Antibacterial (Drug) Resistance Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Antibacterial (Drug) Resistance Market Size by Type (2015-2020)
  • 4.1.1 Global Antibacterial (Drug) Resistance Sales by Type (2015-2020)
  • 4.1.2 Global Antibacterial (Drug) Resistance Revenue by Type (2015-2020)
  • 4.1.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Antibacterial (Drug) Resistance Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Type (2021-2026)
  • 4.2.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Antibacterial (Drug) Resistance Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Indication (2015-2026)

• 5.1 Global Antibacterial (Drug) Resistance Market Size by Indication (2015-2020)
  • 5.1.1 Global Antibacterial (Drug) Resistance Sales by Indication (2015-2020)
  • 5.1.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2015-2020)
  • 5.1.3 Antibacterial (Drug) Resistance Price by Indication (2015-2020)
• 5.2 Antibacterial (Drug) Resistance Market Size Forecast by Indication (2021-2026)
  • 5.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Indication (2021-2026)
  • 5.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Indication (2021-2026)
  • 5.2.3 Global Antibacterial (Drug) Resistance Price Forecast by Indication (2021-2026)

6 North America

• 6.1 North America Antibacterial (Drug) Resistance by Country
  • 6.1.1 North America Antibacterial (Drug) Resistance Sales by Country
  • 6.1.2 North America Antibacterial (Drug) Resistance Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Antibacterial (Drug) Resistance Market Facts & Figures by Type
• 6.3 North America Antibacterial (Drug) Resistance Market Facts & Figures by Indication

7 Europe

• 7.1 Europe Antibacterial (Drug) Resistance by Country
  • 7.1.1 Europe Antibacterial (Drug) Resistance Sales by Country
  • 7.1.2 Europe Antibacterial (Drug) Resistance Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Type
• 7.3 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Indication

8 Asia Pacific

• 8.1 Asia Pacific Antibacterial (Drug) Resistance by Region
  • 8.1.1 Asia Pacific Antibacterial (Drug) Resistance Sales by Region
  • 8.1.2 Asia Pacific Antibacterial (Drug) Resistance Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Type
• 8.3 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Indication

9 Latin America

• 9.1 Latin America Antibacterial (Drug) Resistance by Country
  • 9.1.1 Latin America Antibacterial (Drug) Resistance Sales by Country
  • 9.1.2 Latin America Antibacterial (Drug) Resistance Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Antibacterial (Drug) Resistance Market Facts & Figures by Type
• 9.3 Central & South America Antibacterial (Drug) Resistance Market Facts & Figures by Indication

10 Middle East and Africa

• 10.1 Middle East and Africa Antibacterial (Drug) Resistance by Country
  • 10.1.1 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country
  • 10.1.2 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Type
• 10.3 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Indication

11 Company Profiles

• 11.1 Melinta Therapeutics
  • 11.1.1 Melinta Therapeutics Corporation Information
  • 11.1.2 Melinta Therapeutics Description, Business Overview and Total Revenue
  • 11.1.3 Melinta Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
  • 11.1.5 Melinta Therapeutics Recent Development
• 11.2 Allergan
  • 11.2.1 Allergan Corporation Information
  • 11.2.2 Allergan Description, Business Overview and Total Revenue
  • 11.2.3 Allergan Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 Allergan Antibacterial (Drug) Resistance Products Offered
  • 11.2.5 Allergan Recent Development
• 11.3 Merck
  • 11.3.1 Merck Corporation Information
  • 11.3.2 Merck Description, Business Overview and Total Revenue
  • 11.3.3 Merck Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 Merck Antibacterial (Drug) Resistance Products Offered
  • 11.3.5 Merck Recent Development
• 11.4 Abbott Laboratories
  • 11.4.1 Abbott Laboratories Corporation Information
  • 11.4.2 Abbott Laboratories Description, Business Overview and Total Revenue
  • 11.4.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Products Offered
  • 11.4.5 Abbott Laboratories Recent Development
• 11.5 Pfizer
  • 11.5.1 Pfizer Corporation Information
  • 11.5.2 Pfizer Description, Business Overview and Total Revenue
  • 11.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Pfizer Antibacterial (Drug) Resistance Products Offered
  • 11.5.5 Pfizer Recent Development
• 11.6 GSK
  • 11.6.1 GSK Corporation Information
  • 11.6.2 GSK Description, Business Overview and Total Revenue
  • 11.6.3 GSK Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 GSK Antibacterial (Drug) Resistance Products Offered
  • 11.6.5 GSK Recent Development
• 11.7 PENDOPHARM
  • 11.7.1 PENDOPHARM Corporation Information
  • 11.7.2 PENDOPHARM Description, Business Overview and Total Revenue
  • 11.7.3 PENDOPHARM Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 PENDOPHARM Antibacterial (Drug) Resistance Products Offered
  • 11.7.5 PENDOPHARM Recent Development
• 11.8 Absynth Biologics
  • 11.8.1 Absynth Biologics Corporation Information
  • 11.8.2 Absynth Biologics Description, Business Overview and Total Revenue
  • 11.8.3 Absynth Biologics Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 Absynth Biologics Antibacterial (Drug) Resistance Products Offered
  • 11.8.5 Absynth Biologics Recent Development
• 11.9 Achaogen
  • 11.9.1 Achaogen Corporation Information
  • 11.9.2 Achaogen Description, Business Overview and Total Revenue
  • 11.9.3 Achaogen Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 Achaogen Antibacterial (Drug) Resistance Products Offered
  • 11.9.5 Achaogen Recent Development
• 11.10 Acino Holdings
  • 11.10.1 Acino Holdings Corporation Information
  • 11.10.2 Acino Holdings Description, Business Overview and Total Revenue
  • 11.10.3 Acino Holdings Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 Acino Holdings Antibacterial (Drug) Resistance Products Offered
  • 11.10.5 Acino Holdings Recent Development
• 11.1 Melinta Therapeutics
  • 11.1.1 Melinta Therapeutics Corporation Information
  • 11.1.2 Melinta Therapeutics Description, Business Overview and Total Revenue
  • 11.1.3 Melinta Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
  • 11.1.5 Melinta Therapeutics Recent Development
• 11.12 Austell Laboratories
  • 11.12.1 Austell Laboratories Corporation Information
  • 11.12.2 Austell Laboratories Description, Business Overview and Total Revenue
  • 11.12.3 Austell Laboratories Sales, Revenue and Gross Margin (2015-2020)
  • 11.12.4 Austell Laboratories Products Offered
  • 11.12.5 Austell Laboratories Recent Development
• 11.13 Assembly Biosciences
  • 11.13.1 Assembly Biosciences Corporation Information
  • 11.13.2 Assembly Biosciences Description, Business Overview and Total Revenue
  • 11.13.3 Assembly Biosciences Sales, Revenue and Gross Margin (2015-2020)
  • 11.13.4 Assembly Biosciences Products Offered
  • 11.13.5 Assembly Biosciences Recent Development
• 11.14 Arpida
  • 11.14.1 Arpida Corporation Information
  • 11.14.2 Arpida Description, Business Overview and Total Revenue
  • 11.14.3 Arpida Sales, Revenue and Gross Margin (2015-2020)
  • 11.14.4 Arpida Products Offered
  • 11.14.5 Arpida Recent Development
• 11.15 Demuris
  • 11.15.1 Demuris Corporation Information
  • 11.15.2 Demuris Description, Business Overview and Total Revenue
  • 11.15.3 Demuris Sales, Revenue and Gross Margin (2015-2020)
  • 11.15.4 Demuris Products Offered
  • 11.15.5 Demuris Recent Development
• 11.16 Evolva Holding
  • 11.16.1 Evolva Holding Corporation Information
  • 11.16.2 Evolva Holding Description, Business Overview and Total Revenue
  • 11.16.3 Evolva Holding Sales, Revenue and Gross Margin (2015-2020)
  • 11.16.4 Evolva Holding Products Offered
  • 11.16.5 Evolva Holding Recent Development
• 11.17 ContraFect
  • 11.17.1 ContraFect Corporation Information
  • 11.17.2 ContraFect Description, Business Overview and Total Revenue
  • 11.17.3 ContraFect Sales, Revenue and Gross Margin (2015-2020)
  • 11.17.4 ContraFect Products Offered
  • 11.17.5 ContraFect Recent Development
• 11.18 Cerexa
  • 11.18.1 Cerexa Corporation Information
  • 11.18.2 Cerexa Description, Business Overview and Total Revenue
  • 11.18.3 Cerexa Sales, Revenue and Gross Margin (2015-2020)
  • 11.18.4 Cerexa Products Offered
  • 11.18.5 Cerexa Recent Development
• 11.19 InterMune
  • 11.19.1 InterMune Corporation Information
  • 11.19.2 InterMune Description, Business Overview and Total Revenue
  • 11.19.3 InterMune Sales, Revenue and Gross Margin (2015-2020)
  • 11.19.4 InterMune Products Offered
  • 11.19.5 InterMune Recent Development
• 11.20 Isis Pharmaceuticals
  • 11.20.1 Isis Pharmaceuticals Corporation Information
  • 11.20.2 Isis Pharmaceuticals Description, Business Overview and Total Revenue
  • 11.20.3 Isis Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
  • 11.20.4 Isis Pharmaceuticals Products Offered
  • 11.20.5 Isis Pharmaceuticals Recent Development
• 11.21 Lyndra
  • 11.21.1 Lyndra Corporation Information
  • 11.21.2 Lyndra Description, Business Overview and Total Revenue
  • 11.21.3 Lyndra Sales, Revenue and Gross Margin (2015-2020)
  • 11.21.4 Lyndra Products Offered
  • 11.21.5 Lyndra Recent Development
• 11.22 Microbecide
  • 11.22.1 Microbecide Corporation Information
  • 11.22.2 Microbecide Description, Business Overview and Total Revenue
  • 11.22.3 Microbecide Sales, Revenue and Gross Margin (2015-2020)
  • 11.22.4 Microbecide Products Offered
  • 11.22.5 Microbecide Recent Development
• 11.23 Morphochem
  • 11.23.1 Morphochem Corporation Information
  • 11.23.2 Morphochem Description, Business Overview and Total Revenue
  • 11.23.3 Morphochem Sales, Revenue and Gross Margin (2015-2020)
  • 11.23.4 Morphochem Products Offered
  • 11.23.5 Morphochem Recent Development
• 11.24 Nabriva Therapeutics
  • 11.24.1 Nabriva Therapeutics Corporation Information
  • 11.24.2 Nabriva Therapeutics Description, Business Overview and Total Revenue
  • 11.24.3 Nabriva Therapeutics Sales, Revenue and Gross Margin (2015-2020)
  • 11.24.4 Nabriva Therapeutics Products Offered
  • 11.24.5 Nabriva Therapeutics Recent Development
• 11.25 NanoSafe Coatings
  • 11.25.1 NanoSafe Coatings Corporation Information
  • 11.25.2 NanoSafe Coatings Description, Business Overview and Total Revenue
  • 11.25.3 NanoSafe Coatings Sales, Revenue and Gross Margin (2015-2020)
  • 11.25.4 NanoSafe Coatings Products Offered
  • 11.25.5 NanoSafe Coatings Recent Development
• 11.26 Novexel
  • 11.26.1 Novexel Corporation Information
  • 11.26.2 Novexel Description, Business Overview and Total Revenue
  • 11.26.3 Novexel Sales, Revenue and Gross Margin (2015-2020)
  • 11.26.4 Novexel Products Offered
  • 11.26.5 Novexel Recent Development
• 11.27 Osel
  • 11.27.1 Osel Corporation Information
  • 11.27.2 Osel Description, Business Overview and Total Revenue
  • 11.27.3 Osel Sales, Revenue and Gross Margin (2015-2020)
  • 11.27.4 Osel Products Offered
  • 11.27.5 Osel Recent Development
• 11.28 VenatoRx Pharmaceuticals
  • 11.28.1 VenatoRx Pharmaceuticals Corporation Information
  • 11.28.2 VenatoRx Pharmaceuticals Description, Business Overview and Total Revenue
  • 11.28.3 VenatoRx Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
  • 11.28.4 VenatoRx Pharmaceuticals Products Offered
  • 11.28.5 VenatoRx Pharmaceuticals Recent Development
• 11.29 AAIPharma Services
  • 11.29.1 AAIPharma Services Corporation Information
  • 11.29.2 AAIPharma Services Description, Business Overview and Total Revenue
  • 11.29.3 AAIPharma Services Sales, Revenue and Gross Margin (2015-2020)
  • 11.29.4 AAIPharma Services Products Offered
  • 11.29.5 AAIPharma Services Recent Development
• 11.30 ANTABIO
  • 11.30.1 ANTABIO Corporation Information
  • 11.30.2 ANTABIO Description, Business Overview and Total Revenue
  • 11.30.3 ANTABIO Sales, Revenue and Gross Margin (2015-2020)
  • 11.30.4 ANTABIO Products Offered
  • 11.30.5 ANTABIO Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Antibacterial (Drug) Resistance Market Estimates and Projections by Region
  • 12.1.1 Global Antibacterial (Drug) Resistance Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Regions 2021-2026
• 12.2 North America Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
  • 12.2.1 North America: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
  • 12.2.2 North America: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
  • 12.2.3 North America: Antibacterial (Drug) Resistance Market Size Forecast by Country (2021-2026)
• 12.3 Europe Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
  • 12.3.2 Europe: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Antibacterial (Drug) Resistance Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Antibacterial (Drug) Resistance Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Antibacterial (Drug) Resistance Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Antibacterial (Drug) Resistance Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter’s Five Forces Analysis
• 13.5 Primary Interviews with Key Antibacterial (Drug) Resistance Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Antibacterial (Drug) Resistance Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source